A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis

Summary

This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis. Participants who have completed the core study WA19926 are eligible to participate. Participants will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The anticipated time on study drug is 104 weeks.

Timeline

Start

2012-07

Primary completion

2014-12

Completion

2014-12

Drugs

Indications